Frost & Sullivan Independent Equity Research

Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.


Company: DNA Biomedical Solutions Ltd.        

Sector: Healthcare

Report type: Immediate Update

Published on: 1 July, 2018

DNA research articles: